Malaway

Atovaquone and Proguanil Hydrochloride, the active ingredients in Malaway, are antimalarial agents presented as oral tablets for oral use. They are indicated for the prevention and treatment of Plasmodium falciparum malaria in travelers and patients at risk. The formulation is approved in the European Union and is prescribed by qualified healthcare professionals.

GNH USA supplies Malaway as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malaway (atovaquone/proguanil) is used within the antimalarial therapeutic area to prevent and treat infection by Plasmodium falciparum.

- Prevention of malaria infection (P. falciparum): provides chemoprophylaxis for travelers to endemic regions. - Treatment of acute uncomplicated malaria (P. falciparum): clears parasitemia and resolves clinical symptoms. - Post‑exposure prophylaxis after mosquito bite in endemic areas: reduces risk of developing malaria after possible exposure.

Adverse reactions to Malaway may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain: discomfort in the stomach area. - Dizziness: feeling of light‑headedness. - Vomiting: occasional expulsion of stomach contents. - Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome. - Hepatic dysfunction including elevated transaminases. - Hemolytic anemia, particularly in susceptible individuals. - Severe neutropenia or leukopenia. - Anaphylactic or severe hypersensitivity reactions. - Acute renal failure in rare cases.

When prescribing Malaway, clinicians should consider several precautionary measures to ensure safe use.

- Assess renal function: dose may need adjustment in severe impairment. - Monitor hepatic enzymes: watch for signs of liver injury. - Evaluate pregnancy status: use only if benefits outweigh potential risks. - Counsel breastfeeding mothers: consider infant exposure and risk. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Malaway can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Rifampicin: induces metabolism and markedly reduces atovaquone and proguanil levels. - Carbamazepine: strong CYP450 inducer that lowers drug exposure. - St. John’s wort: herbal inducer that decreases plasma concentrations.

Moderate Interactions (Monitor Closely): - Antacids or sucralfate: may reduce atovaquone absorption if taken simultaneously. - Azole antifungals (e.g., itraconazole): can increase atovaquone levels, requiring monitoring.